Obesity Clinical Trial
Official title:
Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers
This study will find how weight affects the dosing of a drug called anidulafungin. Currently, the amount of anidulafungin a patient receives is the same regardless of the patient's weight. BMI groups were for enrollment purposes only and not used for ordinal data analysis.
This study is designed to measure drug concentrations in the blood of volunteers administered
a single intravenous dose of anidulafungin. The volunteers to be enrolled will not have
either candidiasis or any other fungal infection. This is a single center study. Up to a
total of 35 adult volunteers will be consented for the study at the Clinical and
Translational Research Center (CTRC). Eighteen of these volunteers are needed to complete the
study. The others will likely be screen failures, which is more likely in the BMI > 40 kg/m2
group. Volunteers will be admitted to the CTRC for an overnight stay. Half will be female and
half male. Six volunteers will have a body mass index (BMI) less than 25 kg/m2, six will have
a BMI 25-40 kg/m2, and six will have a BMI greater than 40 kg/m2.
** BMI groups will only be used for patient enrollment and not for data analysis. total body
weight will be used as a continuous variable for data analysis. **
Volunteers will have height and weight measured after they have consented to participate. All
volunteers in each category will receive a single dose of intravenous anidulafungin of 100
mg. The volunteers will have blood drawn via an intravenous catheter just prior to the dose,
and then at 1.5, 8, 16, and 24h after the drug dose. The intravenous catheter is then removed
after the 24h blood draw, and the volunteer discharged from the study. The volunteer will be
asked to return to the CTRC outpatient center at 48 and 72 hours to have the final 2 blood
draws conducted. Subjects who are excluded from study participation due to their laboratory
results will be provided with a copy of their results and an explanation of the reason for
ineligibility.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |